Mikosch P, Gallowitsch H J, Zinke-Cerwenka W, Heinisch M, Pipam W, Eibl M, Kresnik E, Unterweger O, Linkesch W, Lind P
Department of Nuclear Medicine and Endocrinology, PET Centre, Hospital Klagenfurt, Austria.
Acta Med Austriaca. 2003;30(2):41-7. doi: 10.1046/j.1563-2571.2003.03003.x.
The aim of this retrospective study was to evaluate the accuracy of fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) images, which were interpreted under daily routine conditions, in patients with Hodgkin's disease (HD) or non-Hodgkin lymphoma (NHL) for restaging after chemotherapy and/or radiotherapy. For this purpose, 18F-FDG-PET results were compared with morphological imaging methods and the patients' clinical background.
121 PET images of 93 lymphoma patients (44 HD, 49 NHL) were investigated after chemotherapy/radiotherapy. For PET imaging, 160-200 MBq 18F-FDG was administered intravenously, followed by an infusion of 20 mg Furosemid in 250 mL saline. Whole-body 18F-FDG-PET images were obtained using a partial-ring PET scanner without attenuation correction. The morphological imaging consisted in computed tomography and ultrasound (CT/US) in all patients, additional MRI in some patients, and iliac crest biopsy in cases of suspicious bone marrow involvement. The standard of reference was composed of biopsy data, clinical status at the time of investigation, and follow-up of at least 12 months. The PET images were evaluated for their sensitivity, specificity and accuracy based on written reports, which were compiled from other imaging data and the clinical history of the patients.
Sensitivity, specificity, and accuracy of 18F-FDG-PET was 91 %, 81 %, and 85 %; of CT/US, 88 %, 35 %, 56 %, respectively. Major sources of error in 18F-FDG-PET were due to asymmetric muscular hypermetabolism and inflammatory lesions misinterpreted as persistent viable lymphoma tissue. Furthermore, secondary malignancies other than lymphomas were another reason for misinterpretations of 18F-FDG-PET studies.
18F-FDG-PET showed a comparable sensitivity but a higher specificity and accuracy compared with CT/US. To achieve a high accuracy in 18F-FDG-PET, the nuclear medicine specialist needs imaging and clinical data as background information, which can only be acquired through close co-operation with the referring clinicians. Pharmacological muscular relaxation in the course of 18F-FDG-PET imaging may be advisable, as nonspecific muscular hypermetabolism was one of the problems at the image readings and a source of incorrect 18F-FDG-PET interpretations.
这项回顾性研究的目的是评估在日常常规条件下解读的氟-18氟脱氧葡萄糖正电子发射断层扫描(18F-FDG-PET)图像,对霍奇金病(HD)或非霍奇金淋巴瘤(NHL)患者化疗和/或放疗后再分期的准确性。为此,将18F-FDG-PET结果与形态学成像方法及患者的临床背景进行了比较。
对93例淋巴瘤患者(44例HD,49例NHL)化疗/放疗后的121张PET图像进行了研究。进行PET成像时,静脉注射160 - 200 MBq的18F-FDG,随后在250 mL生理盐水中输注20 mg呋塞米。使用无衰减校正的部分环形PET扫描仪获取全身18F-FDG-PET图像。所有患者均进行了计算机断层扫描和超声(CT/US)形态学成像,部分患者还进行了额外的磁共振成像(MRI),对于可疑骨髓受累的病例进行了髂嵴活检。参考标准由活检数据、检查时的临床状况以及至少12个月的随访组成。根据从其他成像数据和患者临床病史汇编的书面报告,评估PET图像的敏感性、特异性和准确性。
18F-FDG-PET 的敏感性、特异性和准确性分别为91%、81%和85%;CT/US的分别为88%、35%和56%。18F-FDG-PET的主要误差来源是不对称的肌肉代谢亢进以及被误判为持续存活的淋巴瘤组织的炎性病变。此外,淋巴瘤以外的继发性恶性肿瘤是18F-FDG-PET研究误判的另一个原因。
与CT/US相比,18F-FDG-PET显示出相当的敏感性,但特异性和准确性更高。为了在18F-FDG-PET中获得高准确性,核医学专家需要影像学和临床数据作为背景信息,而这只能通过与转诊临床医生密切合作来获取。在18F-FDG-PET成像过程中进行药物性肌肉松弛可能是可取的,因为非特异性肌肉代谢亢进是图像解读中的问题之一以及18F-FDG-PET错误解读的一个来源。